An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
PerkinElmer Inc. (NYSE: PKI) will release its first quarter 2023 financial results on May 11, 2023, before market open. A conference call hosted by CEO Prahlad Singh and CFO Max Krakowiak is scheduled for 8:00 a.m. ET on the same day. The company, which is undergoing a name change in the second quarter of 2023, reported approximately $3.3 billion in revenue for 2022 and serves customers across 190 countries. As a significant player in the S&P 500 index, PerkinElmer focuses on providing innovative solutions for disease diagnosis and drug discovery.
Positive
None.
Negative
None.
WALTHAM, Mass.--(BUSINESS WIRE)--
PerkinElmer Inc. (NYSE: PKI), today announced that it will release its first quarter 2023 financial results prior to market open on Thursday, May 11, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.
To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website.
About The PerkinElmer Life Sciences and Diagnostics Company
The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com.